{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Tumor&page=5", "query": { "condition": "Gastroesophageal Junction Tumor", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 400, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Tumor&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Tumor&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:51:37.544Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06265285", "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Esophageal Squamous Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Esophageal Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Carcinoma", "Locally Advanced Urothelial Carcinoma", "Lung Non-Small Cell Carcinoma", "Malignant Solid Neoplasm", "Metastatic Colorectal Carcinoma", "Metastatic Cutaneous Melanoma", "Metastatic Esophageal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Unresectable Cutaneous Melanoma", "Unresectable Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Home Health Encounter", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-04-30", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06265285" }, { "nct_id": "NCT01178944", "title": "Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Undifferentiated Carcinoma", "Gastric Adenocarcinoma", "Gastric Squamous Cell Carcinoma", "Recurrent Esophageal Adenocarcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Gastric Carcinoma", "Stage IIIB Esophageal Adenocarcinoma", "Stage IIIB Esophageal Squamous Cell Carcinoma", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Adenocarcinoma", "Stage IIIC Esophageal Squamous Cell Carcinoma", "Stage IIIC Gastric Cancer", "Stage IV Esophageal Adenocarcinoma", "Stage IV Esophageal Squamous Cell Carcinoma", "Stage IV Gastric Cancer", "Undifferentiated Gastric Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2010-09", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-12-13", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 2, "location_summary": "Buffalo, New York • Rochester, New York", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01178944" }, { "nct_id": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Neoplasms", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2018-10-05", "completion_date": "2025-11-12", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 23, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615326" }, { "nct_id": "NCT01939275", "title": "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Recurrent Gastric Cancer", "Stage IA Gastric Cancer", "Stage IB Gastric Cancer", "Stage IIA Gastric Cancer", "Stage IIB Gastric Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Gastric Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "copper Cu 64-DOTA-trastuzumab", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "DEVICE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DEVICE", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-11-19", "completion_date": "2024-08-05", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01939275" }, { "nct_id": "NCT04161781", "title": "A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophagogastric Cancer", "Esophagus Cancer", "Esophageal Cancer", "Gastric Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Gastroesophageal Junction Squamous Cell Carcinoma" ], "interventions": [ { "name": "18F-BMS-986229 Injection", "type": "DRUG" }, { "name": "IV 18F-BMS-986229", "type": "DRUG" }, { "name": "PET/CT Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-11-12", "completion_date": "2024-03-06", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04161781" }, { "nct_id": "NCT00290719", "title": "Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-11", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290719" }, { "nct_id": "NCT04931654", "title": "A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Gastric Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "AZD7789", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 136, "start_date": "2021-09-28", "completion_date": "2026-08-12", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04931654" }, { "nct_id": "NCT03511222", "title": "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Vorolanib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-09-11", "completion_date": "2020-05-28", "has_results": false, "last_update_posted_date": "2020-07-29", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511222" }, { "nct_id": "NCT02202759", "title": "A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Stomach", "Gastroesophageal Junction Expressing Guanylyl Cyclase C" ], "interventions": [ { "name": "MLN0264", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2014-08-04", "completion_date": "2016-01-15", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 7, "location_summary": "Aurora, Colorado • St. Petersburg, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202759" }, { "nct_id": "NCT02241720", "title": "Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Upper GI Cancer" ], "interventions": [ { "name": "regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-05", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-01-11", "last_synced_at": "2026-10-14T16:51:37.544Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02241720" } ] }